Literature DB >> 8624120

Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.

R Cacabelos1, J Caamaño, M J Gómez, L Fernández-Novoa, A Franco-Maside, X A Alvarez.   

Abstract

CDP-choline was given to patients with Alzheimer's disease (AD) at a daily dose of 1000 mg/day p.o. for one month. This compound slightly improved mental performance, tended to reduce theta activity in fronto-temporal regions, increasing alpha power in occipital areas, and enhanced cerebrovascular perfusion by increasing blood flow velocity and reducing pulsatility and resistance indexes. In addition, CDP-choline diminished histamine and interleukin-1 levels in blood and serum, respectively, and increased plasma TNF.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8624120     DOI： 10.1111/j.1749-6632.1996.tb34452.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  17 in total

1.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

Review 2.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 3.  Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

4.  Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury.

Authors:  Maria V Guseva; Deann M Hopkins; Stephen W Scheff; James R Pauly
Journal:  J Neurotrauma       Date:  2008-08       Impact factor: 5.269

5.  Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.

Authors:  X Antón Alvarez; Carolina Sampedro; Jesús Figueroa; Iván Tellado; Andrés González; Manuel García-Fantini; Ramón Cacabelos; Dafin Muresanu; Herbert Moessler
Journal:  J Neural Transm (Vienna)       Date:  2008-02-14       Impact factor: 3.575

Review 6.  An update on pharmacological treatment options for amblyopia.

Authors:  Aldo Vagge; Lorenzo Ferro Desideri; Carlo Enrico Traverso
Journal:  Int Ophthalmol       Date:  2020-08-07       Impact factor: 2.031

7.  Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome.

Authors:  Salvatore Putignano; Pietro Gareri; Alberto Castagna; Giuliano Cerqua; Pasquale Cervera; Antonino Maria Cotroneo; Francesco Fiorillo; Rodolfo Grella; Roberto Grella; Roberto Lacava; Antonio Maddonni; Saverio Marino; Alice Pluderi; Daria Putignano; Filomena Rocca
Journal:  Clin Interv Aging       Date:  2012-05-10       Impact factor: 4.458

8.  Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.

Authors:  Antonino Maria Cotroneo; Alberto Castagna; Salvatore Putignano; Roberto Lacava; Fausto Fantò; Francesco Monteleone; Filomena Rocca; Alba Malara; Pietro Gareri
Journal:  Clin Interv Aging       Date:  2013-02-05       Impact factor: 4.458

Review 9.  The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives.

Authors:  Pietro Gareri; Alberto Castagna; Antonino Maria Cotroneo; Salvatore Putignano; Giovambattista De Sarro; Amalia Cecilia Bruni
Journal:  Clin Interv Aging       Date:  2015-09-03       Impact factor: 4.458

Review 10.  Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives.

Authors:  Gloria Roberti; Lucia Tanga; Manuele Michelessi; Luciano Quaranta; Vincenzo Parisi; Gianluca Manni; Francesco Oddone
Journal:  Int J Mol Sci       Date:  2015-11-30       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.